A recent study by Labarre et al. [94] investigated the effects of sixteen different probiotic formulations on Caenorhabditis elegans strains that were genetically modified to express two human ALS-associated proteins: fused in sarcoma (FUS) and TAR DNA-binding protein 43 (TDP-43). Here, FUS is linked to amyotrophic lateral sclerosis.